Studies with SLAMF7-specific CARs confirmed the suitability of SLAMF7 as a potential target in Multiple myeloma (MM). Both NK cells and T cells expressing second-generation CARs based on a single chain variable fragment of an antibody related to elotuzumab effectively redirected NK and T cells to secrete cytokines, degranulate and exhibit cytotoxic activity in response to MM cell lines and primary human myeloma cells in vitro. SLAMF7-directed NK and T cells also inhibited tumor growth and prolonged survival in an orthotopic MM xenograft mouse model.
Einsele H, Schreder M. Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab. Therapeutic Advances in Hematology. 2016;7(5):288-301.